Moderna, Inc. (MRNA) stock forecast and price target
Price $223.37 · data as of November 13, 2026
12-month price target
Average target$158.47
Upside / downside−29.1%
Analysts19
ConsensusHold
Low $45.00Average $158.47High $305.00
Gold marker: average target · white marker: today’s price ($223.37)
Analyst ratings
Strong buy 1Buy 3Hold 16Sell 2Strong sell 1
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-7.36 | −1.8% | $2.4B |
| Next fiscal year ends December 31, 2027 | $-4.43 | +43.6% | $2.7B |
| Next quarter ends December 31, 2026 | $-2.14 | −6.3% | $598M |
| Quarter after ends March 31, 2027 | $-1.73 | +47.6% | $281M |
Consensus of the analysts covering Moderna, updated daily. In the last 30 days 6 estimates were raised and 2 lowered.
Frequently asked questions
What is the Moderna stock price target?
The average 12-month target from 19 analysts is $158.47, 29.1% below the current price of $223.37 Targets range from $45.00 to $305.00.
Is Moderna a buy according to analysts?
The consensus rating is “Hold” (1 strong buy, 3 buy, 16 hold, 2 sell, 1 strong sell). Ratings are opinions, not guarantees; this is not investment advice.
How much is Moderna expected to earn?
Analysts expect EPS of $-7.36 for the fiscal year ending December 31, 2026 and $-4.43 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.